On January 27, Suzhou AlphaMa Biotechnology Co., Ltd. (hereinafter referred to as “AlphaMa”) ​​and Suzhou Institute of Drug Innovation Shanghai Institute of Materia Medica (hereinafter referred to as “SUSIMM”) signed a strategic alliance agreement with Hefei KS-V Peptide.

AlphaMa and KS-V Peptide’s representatives signed the “DEL Technology-based Artificial Intelligence Boosted Drug Screening Collaborative Agreement” on the afternoon of January 27. This collaboration will promote the domestic innovative peptide drug R&D industry, a field with broad market potential.

Following the requirements of epidemic prevention and control, AlphaMa Company Chairman Xiaojie Lu did not personally attend the signing ceremony but remotely participated in and witnessed the strategic alliance signing ceremony.

AlphaMa and KS-V Peptide signed a collaborative agreement on artificial intelligence boosted drug screening based on DEL Technology

Left: Li Zhou, general manager of KS-V Peptide; right: Gang Qiao, authorized representative of AlphaMa

Incubated by SUSIMM, AlphaMa applies artificial intelligence to all drug development stages and will bring clinically urgently needed drugs to society with acceptable cost. Their featured drug screening technology is the interactive application of AI with the DNA-encoded compound library (DEL). On the other hand, KS-V Peptide has a high-capacity peptide library, including an in-house customized peptide library and an extensive library of peptide entities, composing a high-throughput screening platform. They search for innovative peptide candidates for known or emerging drug targets, followed by advanced pharmacological research. Because of everyone’s complementary advantages, AlphaMa chairman Xiaojie Lu and KS-V Peptide general manager Li Zhou reached a strategic cooperation intention in artificial intelligence drug screening based on DEL technology, after multiple rounds of communication. Based on each other’s advantages, AlphaMa will use its unique Intelligence DEL (iDEL) platform, and KS-V Peptide will use its novel peptide drug screening platform. Both parties will focus on advancing the interactive application of artificial intelligence, DNA-encoded compound libraries and peptide drug screening technologies, which are also their fields of interest. With the help of these cooperative technologies, the two parties are enthusiastic about the rapid discovery of new peptide lead compounds in the tumor, neurological, and metabolic disease areas. They will also help with the research and development difficulties in pharmaceutical companies to significantly improve efficiency. The collaboration includes, but is not limited to, joint platform construction, team building and training, scientific research communication and transformation, the establishment of an integrated system of technologies and platforms, and active exploration of innovative cooperation models.

At the beginning of the new year of 2021, AlphaMa and SUSIMM have established a comprehensive strategic partnership with KS-V Peptide, which is of great significance! All aspects of the project have reached a new level of industrial plan for the future. AlphaMa, SUSIMM and KS-V Peptide will effectively and actively play their advantages. This integrative strategy, including talents introduction, in-depth communication, and joint promotion of industrial development, will lead everyone to a win-win!

About AlphaMa Biotechnology

Suzhou AlphaMa Biotechnology Co., Ltd. was established in April 2018 with a registered capital of 100 million yuan. It is a new drug R&D company driven by AI and big data, mainly engaged in innovative drug research and development, candidate drug transfer, and related technical development cooperation. AlphaMa applies artificial intelligence to all drug developing stages, especially the interactive application with DNA-encoded compound library screening technology (DEL) to establish a unique Intelligence DEL (iDEL) platform. Utilizing this platform, AlphaMa is committed to developing small molecule drugs for cancerous, neurological, metabolic, and infectious diseases. Their goal is to accelerate drug R&D and bring clinically needed medications to society as soon as possible, using AI and DEL technologies.

About Suzhou Institute of Drug Innovation Shanghai Institute of Materia Medica

It is a key biomedical platform-type project introduced to Suzhou Industrial Park in 2015. The SUSIMM has built a domestic leading new drug R&D technology support chain, including drug discovery, preclinical research, clinical research, API production, preparation pilot test, market production, etc. SUSIMM is committed to developing into an innovative drug R&D center with a global impact. While providing services to new drug R&D companies locally, it also continues to invent new drugs with significant clinical potential.

About KS-V Peptide Bio

Hefei KS-V Peptide Biotechnology Co., Ltd. is a high-tech enterprise dedicated to promoting innovation in peptide drug research and development globally. The company has a cutting-edge drug R&D platform based on chemical synthesis and structural biology, supported by many phenomenal technologies. They provide professional, effective and comprehensive solutions for drug discovery and preclinical development to scientific research institutes, biotechnology and pharmaceutical companies worldwide to help with complex technical issues in peptide drug design.